Dr. Sindhu Johnson is a Rheumatologist, Clinical Epidemiologist and Clinician-Scientist at the University Health Network and Sinai Health Systems. She is also an Associate Professor in the Department of Medicine and the Institute of Health Policy, Management and Evaluation (IHPME) at the University of Toronto; and Program Director of the Clinical Epidemiology & Health Care Research Program at IHPME. Her program of research develops methodologic platforms that combine data-driven and expert-based methods with advanced analytic techniques to define disease states, develop outcome measures, develop guidelines, and study treatment effects. This methodologic work was developed using the model of scleroderma and has now expanded across rheumatic diseases.
She has published >225 articles in peer reviewed journals, secured $5.8 million dollars in salary support and operating grant funding, published 5 book chapters, and invited to 4 Editorial Boards. She has been an investigator for trials that led to the first two US Food and Drug Administration approved medications for scleroderma associated interstitial lung disease (nintedinib (NEJM 2019), tocilizumab (Arthritis Rheum 2020)). She has supervised 18 international clinical research fellows and graduate students, most of who have established Scleroderma Programs in their home countries or now have academic appointments.
Dr. Johnson’s courses include:
- HAD5314 Applied Bayesian Methods in Clinical Epidemiology and Health Care Research, Lecturer
- HAD5302H Measurement in Health Care Research, Lecturer
- HAD6360 Research Internship/Practicum, Supervisor
- HAD5311H Clinical Epidemiology and Health Care Research Comprehensive Course, Course Director
Other Affiliations:
- Clinician-Scientist, University Health Network
- Director, Toronto Scleroderma Program, University Health Network
- Researcher, The Arthritis Society
- Associate Professor, Division of Rheumatology, Department of Medicine, Faulty of Medicine, University of Toronto